Compare Dyne Therapeutics Inc. Common Stock (DYN) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs KLA Corp. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while KLA Corp. trades at $177.43 (market cap $240.12B). The key difference: KLA Corp. is far larger — about 84× Dyne Therapeutics Inc. Common Stock's market cap, and KLA Corp. pays a 0.5% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and KLA Corp. for 60 Days on average.
| DYN | KLAC | |
|---|---|---|
Market Cap | $2.86B | $240.12B |
Volume | 3,341,579 | 10,439,404 |
Sector | Health | Technology |
52-Week High | $26.78 | $301.71 |
52-Week Low | $14.60 | $108.70 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $2.18B | $241.37B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KLA Corporation (KLAC) trades at $178.81, down 5.95% on the day, amid a broader tech selloff. The stock maintains a bullish technical signal, with strong fundamentals including a 35.57% net income margin and consistent earnings beats. Revenue reached $12.16B in 2025, with a robust backlog of $12.57B driven by AI demand, positioning the company for growth in semiconductor equipment.
The outlook remains positive with a consensus price target of $223.88, implying significant upside. Risks include competitive pressures from Applied Materials and ASML, and sensitivity to semiconductor capex cycles. Analyst sentiment is strongly bullish, with 28 buy ratings, supporting a favorable long-term investment case despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
